SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Geriatric Psychiatry and Neurology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Lipkovich, I.
Right arrow Articles by Poole Hoffmann, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lipkovich, I.
Right arrow Articles by Poole Hoffmann, V.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Alzheimer's Disease
*Mental Health
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Weight Changes During Treatment With Olanzapine in Older Adult Patients With Dementia and Behavioral Disturbances

Ilya Lipkovich, PhD

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, lipkovichia{at}lilly.com

Jonna Ahl, PhD

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana

Russell Nichols, PharmD

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana

Thomas Hardy, MD, PhD

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana

Vicki Poole Hoffmann, PharmD

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana

Treatment-emergent weight gain has been reported in younger patients receiving atypical antipsychotics, but less is known about weight gain in adults aged 65 years and older. This was a post hoc analysis of 1267 patients with dementia and behavioral disturbances treated with olanzapine (1 to 20 mg/d) in clinical trials, most of whom were underweight (body mass index <18.5 kg/m2) or of normal weight (body mass index, 18.5-24.9 kg/m2) at baseline. Weight changes over the first 20 weeks of treatment in olanzapine-treated patients, as estimated by a repeated measures analysis model, were significantly greater in the combined categories of underweight and normal weight (1.22 kg and 1.29 kg, respectively) versus overweight and obese (0.56 kg and 0.53 kg, respectively; P = .006). The estimated probability of gaining more than 7% of initial body weight was significantly greater in patients treated with olanzapine versus active comparator (P < .001) or placebo (P < .001). Weight gain in olanzapine-treated older patients with dementia and behavioral disturbances was significantly greater in individuals with a baseline body mass index of less than 25 kg/m2. (J Geriatr Psychiatry Neurol 2007;20:107-114)

Key Words: dementia • weight gain • antipsychotics • older adults • geriatric

Journal of Geriatric Psychiatry and Neurology, Vol. 20, No. 2, 107-114 (2007)
DOI: 10.1177/0891988706298629
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




Advertisement